On Tuesday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) was 5.07% up from the session before settling in for the closing price of $16.75. A 52-week range for CNTA has been $6.65 – $18.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 1.99%. With a float of $90.14 million, this company’s outstanding shares have now reached $131.66 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Centessa Pharmaceuticals plc ADR stocks. The insider ownership of Centessa Pharmaceuticals plc ADR is 31.53%, while institutional ownership is 51.12%. The most recent insider transaction that took place on Dec 17 ’24, was worth 320,634. In this transaction Chief Technology & Quality Ofc of this company sold 17,813 shares at a rate of $18.00, taking the stock ownership to the 147,615 shares. Before that another transaction happened on Dec 16 ’24, when Company’s Chief Technology & Quality Ofc sold 9,611 for $16.36, making the entire transaction worth $157,256. This insider now owns 147,615 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
You can see what Centessa Pharmaceuticals plc ADR (CNTA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 335.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was better than the volume of 0.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.44%. Additionally, its Average True Range was 1.06.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 86.12%, which indicates a significant increase from 55.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.85% in the past 14 days, which was lower than the 62.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.53, while its 200-day Moving Average is $12.44. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $18.28. Second resistance stands at $18.96. The third major resistance level sits at $19.80. If the price goes on to break the first support level at $16.76, it is likely to go to the next support level at $15.92. Assuming the price breaks the second support level, the third support level stands at $15.24.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
There are 131,845K outstanding shares of the company, which has a market capitalization of 2.32 billion. As of now, sales total 6,850 K while income totals -151,090 K. Its latest quarter income was 0 K while its last quarter net income were -42,570 K.
